Government Process
The Drug Enforcement Administration has temporarily placed mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I of the Controlled Substances Act. The order follows a July notice of intent and a three-factor analysis focused on abuse patterns, scope and public-health risk. Temporary scheduling is an emergency administrative mechanism; it subjects manufacture, distribution and possession to Schedule I controls while the government considers longer-term action.
The compounds are chemically related to mitragynine or 7-hydroxymitragynine and act at mu-opioid receptors. Justice Department officials say manufactured products containing MGPI or MGM-15 are marketed for opioid effects and may create dependence or respiratory-depression risks. MGM-16 had not been confirmed in the consumer market when the order was prepared, but DEA cited its potency and potential use as a substitute. Those agency findings support the legal action; clinical outcomes will continue to be studied.
The department drew an important boundary around traditional botanical kratom. Published science has not established MGPI as a naturally occurring kratom alkaloid, but trace findings can arise from processing, storage or analytical conditions. DOJ announced enforcement discretion when only incidental trace MGPI appears in a product otherwise consistent with botanical kratom. That policy is not a statutory exemption and does not apply to concentrated, fortified or intentionally added MGPI, or to MGM-15 and MGM-16.
Process matters because temporary scheduling can move quickly. DEA considered comments from the Department of Health and Human Services and published the order through the Federal Register. Schedule I status can last two years, with a possible extension while permanent scheduling proceedings continue. The order does not by itself determine how FDA will regulate every kratom product, nor does it answer labeling, contamination or state-law questions.
Ruby’s red-tape map: confirmed are the three named substances, immediate controls and enforcement-discretion policy. Alleged in marketing claims are benefits that have not been approved as medical uses. Disputed are the appropriate breadth of federal control and how often trace MGPI occurs naturally or through processing. Unknown are market prevalence, enforcement patterns and permanent status. Expected next are product testing, compliance actions and a possible permanent scheduling record. Read the chemical name, concentration and legal status before treating all kratom products as one category. Retailers and laboratories will need defensible testing methods, chain-of-custody records and concentration evidence if the trace policy becomes central to an enforcement decision. The public record should identify validated detection limits so analytical noise is not mistaken for deliberately fortified product.
Sources
- U.S. Department of Justice — Justice Department Announces Emergency Scheduling of Three Potent Opioid Compounds (08-25-2026)
- Drug Enforcement Administration / Federal Register — Temporary Placement of MGPI, MGM-15 and MGM-16 in Schedule I (08-25-2026)